Interview: Ufuk Kumrulu – Chairman, Polifarma – Turkey
Polifarma is Turkey’s largest producer of basic parenteral IV solutions with a 41 percent market share the country and growing exports across the region. According to the Chairman and CEO…
Polifarma is the leading producer of basic IV and parenteral solutions in Turkey, with a 30 000 square meter production facility in Tekirdag that produces solutions in a variety of forms and volumes, including polypropylene (PP) bags, PP bottles, polyvinyl chloride (PVC) bags, and glass bottles. Starting in 2011, Polifarma began to expand their business into hospital IV soultions as well, and leads the Turkish market in a certain categories with premixed hospital IV solution products, and has developed an aseptic production line to support their growth in the hospital solutions market.
Contact Details
Capital Tower
Halkali Merkez Mah. Basin Ekspres Yolu No: 9 Kat: 6
P.C.: 34259 Halkali/Istanbul/Turkey
Phone: +90 (212) 481 00 13-17
Fax: +90 (212) 481 00 73
info@polifarma.com.tr
export@polifarma.com.tr
Polifarma is Turkey’s largest producer of basic parenteral IV solutions with a 41 percent market share the country and growing exports across the region. According to the Chairman and CEO…
Consumer healthcare products manufacturer Winalite is working to penetrate the Turkish market, but with regulations complicating bringing their portfolio from China, general manager Arafat Yadigar is looking to develop a…
Ozgur Tomruk, J&J’s Managing Director for Global Surgery talks about Turkey’s importance for the company, the priorities they have set, J&J’s commitment to quality and his ambition for the company’s…
Nil Tunaşar, managing partner of Transorient, discusses significance of tracking performance metrics among 3PL providers, the organization’s technology overhaul, and also highlights the type of logistics solutions encompassed under Transorient’s…
Matthias Diewald (MD) and Asli Volkan (AV) elaborate on HELM Kimya’s longstanding presence within Turkey and the type of market opportunities available for co-development and contract manufacturing. They also explain the…
Haluk Ataoglu, academic turned founder of Matriks Biotek®, talks about his aspirations for his company and the Turkish R&D landscape as well as how to penetrate the global pharmaceutical market…
Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the…
BMS Turkey’s new general manager discusses Opdivo (nivolumab) their revolutionary new product for squamous non-small cell lung cancer, their registry of 1200 patients in Turkey with melanoma, potential developments in pharmaceutical…
Multinational R&D investment in Turkey, particularly investment in clinical trials, has been quite limited relative to the size of the Turkish pharmaceutical market. Turkish R&D spending amounted to just 0.95…
Over the past six years, Turkey has consistently lowered its drugs prices and guided its companies to greater efficiency. “Reference prices in Turkey are constructed from the lowest price in…
In the coming years, Turkey plans to prioritize R&D initiatives, health studies and medical innovation: that’s the core message Minister of Health Mehmet Müezzinoğlu gave PharmaBoardroom. This is the beginning…
Recep Altekin, the general manager of MT Sağlik – market leader in Turkey for blood glucose monitoring systems and diabetes test strips by volume – tells PharmaBoardroom about his company’s impact…
AstraZeneca’s Country President for Turkey discusses their efforts to build scientific leadership in Turkey in line with their global strategy and her hopes for the market access and public-private partnership…
See our Cookie Privacy Policy Here